Fibrocell Technologies, Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Exton PA United States (1994)
Status: Acquired by Castle Creek Pharmaceuticals (2019)

Organization Overview

First Clinical Trial
2006
NCT00655889
First Marketed Drug
2011
azficel-T (Laviv)
First NDA Approval
2011
azficel-T (Laviv)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Fibrocell Science | Fibrocell Technologies, Inc.

Active Ingredients

Marketed Drugs (1)

azficel-T (Laviv) (2011 NDA)

Drugs in Phase 3 Trials (2)

azficel-T (Laviv) (8 trials)

fcx-007 (2 trials)

Drugs in Phase 2 Trials (2)

fcx-013 (1 trial)

veledimex (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 2)

Cicatrix (Phase 3)

Dysphonia (Phase 2)

Epidermolysis Bullosa (Phase 3)

Epidermolysis Bullosa Dystrophica (Phase 3)

Facies (Phase 2)

Hoarseness (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Localized (Phase 2)

Scleroderma, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 4